Alternative splicing in a presenilin 2 variant associated with Alzheimer disease

Jacquelyn E. Braggin(University of Washington), Suman Jayadev(University of Washington)

Annals of Clinical and Translational Neurology

March 10, 2019

10.1002/acn3.755

Cited by 44

Related Papers

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

|Nature Medicine|2021|365

Agonist-Induced Phosphorylation of the Angiotensin AT1a Receptor Is Localized to a Serine/Threonine-Rich Region of Its Cytoplasmic Tail

|Molecular Pharmacology|1998|74

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

|The Lancet Neurology|2025|39